IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Truist Securities Downgrades IGM Biosciences (IGMS) to Hold
October 1, 2024 6:52 AM EDTTruist Securities analyst Asthika Goonewardene downgraded IGM Biosciences (NASDAQ: IGMS) from Buy to Hold with a price target of $12.00 (from $24.00).
The analyst comments "What started as a side-hustle is now a full scale pivot - IGMS is now solely focused on autoimmune... More
IGM Biosciences (IGMS) PT Lowered to $17 at RBC Capital
October 1, 2024 6:32 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on IGM Biosciences (NASDAQ: IGMS) to $17.00 (from $20.00) while maintaining a Outperform rating.
The analyst comments "While discontinuation of aplitabart is disappointing, evolution into a pure-play autoimmune company with T-cell engagers should streamline... More
Jefferies Reiterates Buy Rating on IGM Biosciences (IGMS)
October 1, 2024 6:16 AM EDTJefferies analyst Roger Song reiterated a Buy rating and $48.00 price target on IGM Biosciences (NASDAQ: IGMS)
The analyst comments "We caught up with mgmt. Co has focused on autoimmune franchise for a while, along with partner Sanofi's recent strategic shift, so... More
Morgan Stanley Reiterates Equalweight Rating on IGM Biosciences (IGMS)
October 1, 2024 6:09 AM EDTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)
The analyst comments "IGM announced multiple updates, including a pipeline reprioritization focused on T cell engagers for autoimmune diseases and discontinuation of oncology development,... More
IGM Biosciences Inc. (IGMS) Falls 27% After Announcing Plans to Prioritize its Pipeline of T Cell Engagers
September 30, 2024 4:13 PM EDTIGM Biosciences Inc. (NASDAQ: IGMS) Falls 27% After Announcing Plans to Prioritize its Pipeline of T Cell Engagers
Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus... More